2020 Transplant Hepatology Board Review Course

4.67 (45 votes)

Recorded On: 09/23/2020

The 2020 AASLD Transplant Hepatology Board Review Course set for August 15-16 in Dallas, TX is now an on-demand course. This on-demand course will release on Friday, August 15, 2020.  For further questions contact education@aasld.org. 

This course will help prepare physicians for the American Board of Internal Medicine (ABIM) and American Board of Pediatrics (ABP) certification and maintenance of certification (MOC) exam in transplant hepatology and pediatric transplant hepatology as it reflects the updated ABIM/ABP Transplant Hepatology Certification Exam blueprint. High yield clinical topics will be presented by leaders in the field of hepatology and transplant medicine. Designed for ABIM/ABP Transplant Hepatology exam preparation, the course also provides a comprehensive review of up-to-date management of liver transplant patients.

COMPONENTS
Online presentations comprised of PowerPoint slides and accompanying audio, online pre- and post-tests and evaluations:
- 25 online, narrated presentations 20 - 45 minutes in length 
- MOC quiz questions for each session
- Evaluation for CME credit/ABIM and ABP MOC point offerings 

DIRECTIONS
Review all section tabs before you begin. Start watching the presentation videos. Complete necessary components to claim either CME and ABIM and or ABP MOC.

HANDOUTS
To access, download and print the PDFs of each presentation, please head to the Handouts tab.  Note, you will need to download the PDF to your device to proceed with printing. 

COURSE FEEDBACK
Once you have watched the content, come and share your questions and feedback by heading to the course's AASLD Engage Page.  Based on the feedback from the AASLD Engage page and the supplemental survey to be sent in late August, AASLD might host real-time Q&A webinars based on your comments and questions about the content in mid-September. 

CANCELLATION POLICY
Requests for cancellation must be submitted in writing to meetings@aasld.org. Cancellations received:

- Through August 14, 2020 at 11:59PM are subject to a $75.00 cancellation fee.
- August 15, 2020 and after are non-refundable.

CONTINUING EDUCATION 
Continuing Medical Education (CME): 9.25 AMA PRA Category 1 Credits™
ABIM Maintenance of Certification (MOC): 9.25 ABIM MOC Points
ABP Maintenance of Certification (MOC): 9.00 ABP MOC Points

HOW TO EARN AND CLAIM MOC POINTS
To claim both CME Credits and ABIM and or ABP MOC points for this activity you must:  

             o    Watch each video presentation
             o    Complete each session post-test and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing score.   
             o    Complete the Final Evaluation
             o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.
MOC points are available for ABIM and or ABP board certified physicians only.

Release Date: August 15, 2020
Expiration Date: December 31, 2022

COPYRIGHT 
All faculty in this activity have given their permission for publication ©2020 AASLD. 

Andrew I. Aronsohn

Andrew Aronsohn is an Associate Professor of Medicine in the Center for Liver Diseases at the University of Chicago Medical Center. Dr. Aronsohn is the program director for the Gastroenterology fellowship at the University of Chicago. In addition, Dr. Aronsohn is a faculty member at the MacLean Center for Clinical Medical Ethics at the University of Chicago and is the co-director of the Pritzker School of Medicine Doctor Patient Relationship course.  Dr. Aronsohn research interests involve HCV education, access to care and elimination. He is the co-principal investigator of HepCCATT, an initiative to diagnose, link to care and treat HCV in the Chicago area. This project utilizes telehealth technology to expand HCV management into the primary care setting.  Dr. Aronsohn is the co-lead of the treatment experienced section of the AASLD / IDSA HCV guidance writing committee as was a member of National Academies of Medicine committee which wrote “A National Strategy for the Elimination of Hepatitis B and C”. He also has a busy clinical practice, which includes both general and transplant hepatology.

Oren K. Fix

Dr. Oren Fix is the Medical Director of the Liver Transplant Program at Swedish Medical Center in Seattle, Washington, Clinical Associate Professor at the Washington State University Elson S. Floyd College of Medicine, and Associate Provider Informaticist at Providence St. Joseph Health. He is board certified in Transplant Hepatology, Gastroenterology, Internal Medicine, and Clinical Informatics. He is the co-chair for the AASLD COVID-19 Task Force's Clinical Oversight Subcommittee, and serves on the AASLD Nominating Committee, Online Learning Committee, and the GI/Transplant Hepatology Pilot Steering Task Force. He is on the editorial boards of Liver Transplantation and Hepatology Communications. Past service to AASLD includes chair of the Training and Workforce Committee and chair of the MOC Committee.

Jacquelyn F. Fleckenstein

Dr. Fleckenstein is a Professor of Medicine in the Division of Gastroenterology and Hepatology at Washington University School of Medicine in St. Louis, Missouri.  She is interested in the management of advanced cirrhosis and pregnancy related liver disease.  She serves as the director of the liver transplant fellowship program at Washington University and she has served on several AASLD committees. 

Catherine Frenette

Catherine Frenette is the Medical Director of Liver Transplant at the Scripps Center for Organ Transplant, Scripps Green Hospital, La Jolla, CA. She is also the Medical Director of the Liver and Hepatocellular Cancer Program at the Scripps MD Anderson Cancer Center. Catherine underwent medical training at Rush Medical College in Chicago, IL. She then completed internal medicine training at Scripps Mercy Hospital in San Diego, CA, and subsequently underwent training in gastroenterology with a focus on transplant hepatology at Scripps Clinic in La Jolla, CA. Since joining Scripps in 2012, Catherine has worked diligently to provide excellent medical care to patients with end stage liver disease and liver cancer. In addition to directing two major medical programs in Southern California, Catherine has been the Principle or Co-Investigator for multiple clinical trials related to liver disease and liver cancer. She also serves a key role in the training of gastroenterology fellows, as well as internal medicine residents. Catherine has also served the community through the American Liver Foundation, where she serves as vice-chair of the local Medical Advisory Committee and is also on the National Executive Committee. She has been awarded Fellow Status of the American Society of Transplantation and has also been awarded Fellow of the American Gastroenterology Association.

I have worked diligently in the transplant world for more than a decade, where I have been active in local and regional meetings, attending nearly every regional meeting in the past 12 years. I also have been active in meetings regarding policy, attending national meetings to discuss liver redistricting and participating in the American Transplant Society Liver and Intestinal Community of Practice Policies Subcommittee. I have a unique perspective regarding transplantation, because I am also a donor family member. This allows me to truly understand all parties involved in transplant, including the donor, the recipient, as well as the transplant programs and organ procurement organizations. I have served on many committees throughout my career and am committed to continuing to serve the transplant community as an Associate Councillor.

Stevan A. Gonzalez

Dr. Stevan Gonzalez is the medical director of liver transplantation at the Baylor Simmons Transplant Institute at the Baylor Scott & White All Saints Medical Center in Fort Worth, Texas. He is a graduate of Dartmouth Medical School and completed his training in internal medicine, gastroenterology, and hepatology at the New York-Presbyterian Weill Cornell Medical Center in New York, at which time he received a Master of Science degree in biostatistics at the Columbia University Mailman School of Public Health. He then completed a transplant hepatology fellowship at Stanford University Medical Center. He has worked as a transplant hepatologist with the Baylor program in Fort Worth and Baylor University Medical Center in Dallas since 2008, and has served as the medical director of liver transplantation at Baylor in Fort Worth since 2015. He has maintained an active role in organ transplantation, medical education, and research as an Associate Professor in the Department of Internal Medicine at the TCU and UNTHSC School of Medicine. His clinical and research interests include viral hepatitis and liver transplantation, portal hypertension, and kidney dysfunction in cirrhosis.

Janice Jou

Janice Jou, MD, MHS is a transplant hepatologist in the VA Portland Healthcare System and Associate Professor in the Division of Gastroenterology and Hepatology at Oregon Health and Science University. Dr. Jou is also the program director for the gastroenterology fellowship at OHSU and is actively involved in leading educational activities for the American Association for the Study of Liver Diseases and the American Gastroenterological Association. Her research interests include outcomes for hepatocellular carcinoma and processes of care in chronic liver disease.

Laura M. Kulik

I am a Professor of Medicine in the Division of Gastroenterology and Hepatology, and am Certified in both Gastroenterology and Hepatology and in Transplant Hepatology. My major clinical research focus is on the therapy and diagnosis of hepatocellular carcinoma. I work in a muliti-disciplinary medical/radiologic/surgical Liver Tumor clinic, and am involved in the recruitment of patients with HCC into clinical or pathologic trials. My major interest is on loco-regional therapy for HCC, both as a primary therapy and as a bridge to liver transplantation, including 90Yttrium radiotherapy and TACE.

Josh Levitsky

Josh Levitsky, MD, MS is currently a Professor of Medicine and Surgery in the Division of Gastroenterology & Hepatology at the Northwestern University Feinberg School of Medicine. Dr. Levitsky received his B.S. from the University of Michigan and M.D. from the Albert Einstein College of Medicine where he was elected to Alpha Omega Alpha. He then completed an Internal Medicine residency and Gastroenterology fellowship at the University of Chicago Hospitals and a Transplant Hepatology fellowship at the University of Nebraska Medical Center, receiving an AASLD Fellowship Award. At Northwestern, he completed a Master of Science in Clinical Investigation. He is currently certified by the American Board of Internal Medicine in Gastroenterology and Transplant Hepatology.

Dr. Levitsky’s academic interests are clinical and translational in nature, with a focus on liver transplant immunosuppression, tolerance and biomarkers. He has published numerous peer-reviewed journal articles, abstracts, book chapters and reviews on topics relevant to liver disease and transplantation. He is a Deputy Editor for the American Journal of Transplantation. He is the principal and co-investigator for a number of NIH, pharmaceutical and investigator-initiated trials. At Northwestern, he is currently the Gastroenterology Program Director and Director of Liver Research. He has been elected to the Feinberg Academy of Medical Educators and has received several teaching awards.

Dr. Levitsky is an active member of several professional societies, including the American Society of Transplantation, American Association for the Study of Liver Diseases, and the International Liver Transplantation Society. He was previously a Councilor-At-Large for the American Society of Transplantation from 2014-2017. He was a prior chair of the American Transplant Congress, recent co-chair of AST’s CEOT meeting and is the current co-chair of the AST Education Committee. One of his passions is trainee education, establishing the AST Comprehensive Trainee Curriculum and regularly participating in the yearly Fellow’s Symposium. Dr. Levitsky’s dedication to the field of transplantation and AST includes all facets of clinical care, advocacy, research and education.

Michael R. Lucey

Dr Michael Ronan Lucey was born in Dublin, Ireland, and was educated at Trinity College, Dublin, graduating with the degrees of M.B., B.Ch in 1976.  He was awarded an M.D. by thesis in 1985. He completed his internship at the Meath Hospital, Dublin and residency in Internal Medicine at the Federated Dublin Voluntary Hospitals.  He was a fellow in Gastroenterology at Saint Bartholomew's Hospital, and a fellow in Liver Diseases in Kings College Hospital, both in London, England.  In 1985 he came to the University of Michigan, first as a fellow and then as faculty in the Division of Gastroenterology.  While at the University of Michigan, he became Medical Director of the liver transplant program.  From 1995 to 2001, he was Director of Hepatology at the University of Pennsylvania.  In 2001until the present,  he has been Professor of Medicine, Chief of the Division of Gastroenterology and Hepatology at the University of Wisconsin School of Medicine and Public Health. 

Dr Lucey's research interests include selection for and outcome of liver transplantation, alcoholic liver disease, and management of end-stage liver disease.  Dr Lucey was president of the American Society of Transplantation in 2003. He was treasurer of the American Association for the Study of Liver Diseases from 2007 to 2010. 

He was Editor in Chief of Clinical Liver Disease, the on-line educational journal of the AASLD from 2011 to 2017.  

Henry C. Lin

Dr. Lin is a pediatric hepatologist and gastroenterologist at Doernbecher Children's Hospital.  His research focus is on pediatric liver disease and assessing strategies to improve access to this specialized care.  He also conducts research on physician-caregiver-patient communication strategies and the impact on outcomes. Dr. Lin is passionate about teaching medical students and trainees. In his spare time, Dr. Lin enjoys rock climbing, barefoot running, and trying new recipes.  

Erin Maynard

Erin Maynard, MD, FACS, is Associate Professor of Surgery at Oregon Health and Science University, Associate Program Director of the General Surgery Residency Program,  Section Chief and Surgical Director of Liver Transplant at the Portland VA Medical Center in Portland, OR.

Dr. Erin Maynard received her Bachelor of Science Degree at Ohio University in Athens, OH before completion of medical school at The Ohio State University, Columbus, OH. She then completed her surgical residency at Maine Medical Center in Portland, ME before completing her training in Abdominal Organ Transplantation and Hepatobiliary Surgery at Washington University in St. Louis, MO.  She went on to practice multi-organ abdominal transplant at the University of Kentucky before being recruited to Oregon Health and Science University.  Her interests at the university are focused on adult multi-organ transplantation, as well as, both benign and malignant hepatopancreaticobiliary surgery.  She is also actively engaged in resident and fellow education and focuses her research interests on clinical outcomes, hepatocellular carcinoma, and liver transplantation. 

K. Gautham Reddy

Gautham Reddy, MD is a transplant hepatologist and gastroenterologist who currently serves as the Associate Chief in the Section of Gastroenterology, Hepatology & Nutrition at The University of Chicago Medicine. He has an avid interest in medical education and previously served for many years as the Program Director for both the Gastroenterology Fellowship and the Transplant Hepatology Fellowship at The University of Chicago. He has been a recipient of teaching and mentorship awards and has served on multiple AASLD and ACG committees related to training and education. His research interests include novel therapeutics for rare hepatology conditions and medical education.

Mark W. Russo

Mark W. Russo, MD, MPH, FAASLD is Medical Director of Liver Transplantation, Chief, Division of Hepatology, and Clinical Professor of Medicine at Carolinas Medical Center-Atrium Health. In the AASLD, Dr. Russo is Chair of the Maintenance of Certification Committee, member of the Nominating Committee, co-director of the 2020 AASLD Transplant Hepatology Board Review course, and member of a working group planning for the future hepatology workforce. He is an Associate Editor for the American Journal of Gastroenterology and serves on the editorial board of Expert Reviews in Gastroenterology and Hepatology and the Journal of Clinical Medicine.  He has more than 100 peer-reviewed publications and editor of the textbook Diagnosis and Management of Autoimmune Hepatitis.

Amit G. Singal

Dr. Singal is a Professor of Internal Medicine, Chief of Hepatology, and Medical Director of the Liver Tumor Program at UT Southwestern Medical Center in Dallas, TX. He has obtained state, DOD and NIH funding to examine the HCC care continuum, ranging from HCC prevention to screening and early detection to treatment and survivorship. Dr. Singal has published over 150 scientific papers regarding HCC screening and treatment. For his work, he has been awarded the David Bruton Professorship in Clinical Cancer Research and Blue Faery Award for Excellence in Liver Cancer Research.

Ryan M. Taylor

Ryan M. Taylor, MD, MS is Associate Professor of Medicine in the Division of Gastroenterology/Hepatology, Department of Internal Medicine, at the University of Kansas School of Medicine where he is Medical Director of Liver Transplantation and Medical Director of Hepatology.  After obtaining his medical doctorate at the University of Missouri-Kansas City School of Medicine, Dr. Taylor completed his residency in Internal Medicine and his fellowship in Gastroenterology/Hepatology as well as Transplant Hepatology at the University of Michigan School of Medicine in Ann Arbor.  Dr. Taylor was a 2006-2007 American Association for the Study of Liver Diseases Advanced Hepatology Award recipient.   During his fellowship training he also completed a Masters of Science degree in Clinical Research Design and Statistical Analysis through the University of Michigan School of Public Health.  

Lisa VanWagner

Dr. Lisa VanWagner is an Assistant Professor of Medicine-GI & Hepatology and Preventive Medicine-Epidemiology at Northwestern University in Chicago, IL.  Dr. VanWagner utilizes human population-based approaches, large electronic health record data analysis and health services research methods to define and characterize cardiovascular disease (risk prediction, prevention and treatment approaches in patients with chronic liver disease.  Notably, she leads the multicenter Advancing Liver Therapeutic Approaches (ALTA) Consortium Study Group for the Management of Portal Hypertension and is the lead Principal investigator for ALTA TIPS, a U.S. based longitudinal observational study of patients who are undergoing transjugular intrahepatic portosystemic shunt (TIPS) placement. ALTA will create a database that will provide clinical parameters and outcomes of patients undergoing TIPS as part of their standard of care in hopes of answering key clinical questions about the utilization, outcomes and best practices surrounding TIPS as a therapeutic intervention for the complications of portal hypertension.  She is an active member of AASLD, currently serving as a member of the Practice Guidelines Committee and is an Associate Editor for Liver Transplantation and Clinical Liver Disease.

Zobair M. Younossi

Zobair M Younossi is the President of Inova Medicine as well as Professor and Chairman of the Department of Medicine at Inova Fairfax Medical Campus, Falls Church, Virginia, USA. He is also Chair of Clinical Research, Inova Health System, Falls Church, Virginia. Dr. Younossi earned his medical degree from the University of Rochester School of Medicine and Dentistry (Alpha Omega Alpha 1989) in Rochester, NY, USA. He then completed his residency in internal medicine with a fellowship in gastroenterology and hepatology at Scripps Clinic and Research Foundation in La Jolla, California, USA, while earning his master of public health degree with multiple honours from San Diego State University School of Public Health, San Diego, California, USA. He served as Staff Hepatologist and Senior Researcher at the Cleveland Clinic Foundation, Cleveland, Ohio, USA, before establishing the Canter for Liver Diseases at Inova Fairfax Hospital, which is now renowned for research related to outcomes research in liver disease and clinical, health services and translational research in non-alcoholic fatty liver disease (NAFLD). He has served as Vice President of Research for Inova Health System and currently serves as the Chair of Research for Inova Health System. He also serves as the President and Chairman of the Board of Trustees of the Chronic Liver Disease Foundation (2018-Present) and the Board of Inova Health System Foundation (2011-Present). He was appointed by Governors T Kaine and B McDonnell of Virginia to the Board of Directors of Virginia Biotechnology Research Partnership Authority (2008-2014). He also served Virginia Tobacco & Health Research Repository (VTHRR), Board of Directors, America Heart Association, Mid-Atlantic Affiliate (2010-2012) and Board of the American College of Gastroenterology Institute for Clinical Research & Education (2013-Present). Finally, he has served on multiple committees for American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastrointestinal Association and George Mason University as well as numerous committees at Inova Fairfax Medical Campus and Inova Health System.

Over the past 3 decades, Dr. Younossi has pioneered research in NAFLD and has been a leader in the field of patient-reported outcomes (PROs), economic assessment and other areas of outcomes research in liver disease. He leads a number of international efforts related to NAFLD and PROs in liver disease though global collaborations, including the Chair of Global NASH Council and the Global Liver and NASH Registries. His research in both NAFLD and outcomes research is highly cited and he a highly sought-after speaker for National and International Scientific meetings. In addition to research and administrative duties, Dr. Younossi has been actively involved in teaching patients (through America Liver Foundation) students (Both medical students and post graduate students), residents and GI/Hepatology fellows. He has also served as Chair, Director or faculty of a number international scientific and CME related courses. He is also the Chair of the Global NASH Council and Global NASH Registry.

Dr. Younossi specializes in hepatology and gastroenterology and has authored over 560 articles, 3 books, 6 journal supplements, over 25 book chapters and over 900 abstracts at the international scientific meetings. He is highly sought-after speaker providing over 430 faculty lectures in national and international meetings. His academic productivity has led to an H-index of 88. Dr.Younossi has also served as the co-editor of Liver International, Associate Editor of J of Hepatology and on the editorial board of a number of important medical journals. He has represented the American Association of Liver Disease and American Gastroenterological Association at different congressional meetings.

Carl L. Berg

Dr. Berg is Professor of Medicine and Medical Director of Abdominal Transplantation at Duke University.  He has been a director of liver transplant programs for more than 20 years, and trained nearly twenty transplant hepatologists over that time frame.  He has served in numerous national roles related to management of the US transplant system, including as President of UNOS.  His research interests focus on expanding the donor pool to better match organ demand, as well as utilization of organs previously considered as “marginal”.

 

David Levi

David Levi, MD, FACS is a transplant surgeon at Carolinas Medical Center in Charlotte, NC. He is a Professor of Surgery in the Department of Surgery at UNC-Charlotte Campus. He has been at Carolinas Medical Center since 2012.

He received his Bachelor of Arts in Biology, graduating Magna Cum Laude with Phi Beta Kappa distinction from Wabash College in Indiana.  He completed his MD at the University Of Miami Miller School Of Medicine graduating with AOA recognition and completed his general surgery residency and transplant surgery fellowship at Jackson Memorial Hospital. He joined the faculty at the Miller School of Medicine at the University of Miami in 1999. He was promoted to the level of Clinical Professor of Surgery and was selected to the Iron Arrow Honor Society.  Dr. Levi is board certified in surgery and is a Fellow of the American College of Surgeons.  He is a member of the Southern Surgical Association, the American Society of Transplant Surgeons, and The American Association for the Study of Liver Diseases, the Transplantation Society, the International Liver Transplant Society and the Americas Hepato-Pancreato Biliary Association.  His clinical interests include liver transplantation, hepatobiliary surgery, and the multidisciplinary management of liver cancer. An author of more than 200 publications and abstracts including original manuscripts, reviews and book chapters, his academic and research interests primarily focus on the clinical aspects of liver transplantation, hepatobiliary surgery, the management of HCC, and surgical outcomes and quality.

Jennifer C. Lai

Dr. Lai is a transplant hepatologist, Associate Professor In Residence at the University of California, San Francisco and Director of the UCSF Hepatology Clinical Research.

Her long-term mission is to help patients with end-stage liver disease survive to and thrive after liver transplantation. Her primary research focuses on integrating core geriatric principles, such as frailty and palliative care, into the day-to-day practice of hepatology and transplant medicine to improve the care of her patients. She is the founder and principal investigator of the NIH funded Functional Assessment in Liver Transplantation (FrAILT) Study, a multi-center collaboration aimed at investigating the impact of frailty on liver transplant outcomes. She serves as an Associate Editor for the American Journal of Transplantation and Editorial Board Member of Hepatology and Liver Transplantation journals, as well as a standing member of the FDA GI Drug Advisory Committee. In 2020, she was appointed chair the AASLD Practice Guidance on Frailty, Sarcopenia, and Malnutrition. In recognition of the importance of her work, Dr. Lai has been named a NIH Beeson Scholar in Aging Research by the National Institute on Aging and was awarded the American Gastroenterological Association Young Investigator Award in 2020.

Michael D. Leise

Dr. Leise finished his internal medicine residency, chief residency, Gastroenterology and Transplant Hepatology fellowships at Mayo Clinic, Rochester.  He is an Assistant Professor of Medicine with research interests in Hepatitis C, hepatic encephalopathy, and liver transplant outcomes.

Peter Chin-Hong

Peter Chin-Hong is Associate Dean for Regional Campuses. He is a medical educator who specializes in treating infectious diseases, particularly infections that develop in patients who have suppressed immune systems, such as solid organ and hematopoietic stem cell transplant recipients and HIV+ organ transplant recipients. He directs the immunocompromised host infectious diseases program at UCSF. His research focuses on donor derived infections in transplant recipients and molecular diagnostics of infectious diseases in patients with suppressed immune systems. He earned his undergraduate and medical degrees from Brown University, before completing an internal medicine residency and infectious diseases fellowship at UCSF, where he is Professor of Medicine and Director of the Yearlong Inquiry Program in the School of Medicine. He was the inaugural holder of the Academy of Medical Educators Endowed Chair for Innovation in Teaching. He was a member of UNOS/OPTN Disease Transmission Advisory Committee and is Associate Medical Director of Donor Network West.

Key:

Complete
Failed
Available
Locked
Session I
General Board Presentation
Open to view video.
Open to view video.
Metabolic and Genetic Diseases
Open to view video.
Open to view video.
Cholestatic and Autoimmune Liver Diseases
Open to view video.
Open to view video.
Hepatitis A, B, C, D, E Virus Infection: Pre- and Post-Liver Transplantation
Open to view video.
Open to view video.
Pregnancy and Liver Disease
Open to view video.
Open to view video.
Acute Liver Failure and the Liver ICU Patient
Open to view video.
Open to view video.
Alcohol-associated Liver Disease Pt. 1
Open to view video.
Open to view video.
Alcohol-associated Liver Disease Pt. 2
Open to view video.
Open to view video.
Portal Hypertension
Open to view video.
Open to view video.
Selection and Evaluation for Transplantation
Open to view video.
Open to view video.
Nutritional Support in Patients with Cirrhosis
Open to view video.
Open to view video.
Perioperative Complications
Open to view video.
Open to view video.
Session I Quiz
20 Questions  |  Unlimited attempts  |  14/20 points to pass
20 Questions  |  Unlimited attempts  |  14/20 points to pass
Session II
Donor Selection
Open to view video.
Open to view video.
Transplant Immunology
Open to view video.
Open to view video.
Immunosuppression and Rejection
Open to view video.
Open to view video.
Liver Transplantation for Cholangiocarcinoma and Other Tumors
Open to view video.
Open to view video.
Liver Transplantation for Nonalcoholic Fatty Liver Disease (NAFLD)
Open to view video.
Open to view video.
Liver Transplantation 101 for the Hepatologist
Open to view video.
Open to view video.
Session II Quiz
11 Questions  |  Unlimited attempts  |  7/11 points to pass
11 Questions  |  Unlimited attempts  |  7/11 points to pass
Session III
Pediatric Topics
Open to view video.
Open to view video.
HCC and Post-Transplant Malignancy
Open to view video.
Open to view video.
Post Liver Transplant Infectious Complications
Open to view video.
Open to view video.
Recurrence of Disease After Liver Transplantation
Open to view video.
Open to view video.
Long Term Complications Post Liver Transplant
Open to view video.
Open to view video.
Potpourri
Open to view video.
Open to view video.
Ethics and Liver Transplantation
Open to view video.
Open to view video.
Statistics for the Boards
Open to view video.
Open to view video.
Session III Quiz
13 Questions  |  Unlimited attempts  |  9/13 points to pass
13 Questions  |  Unlimited attempts  |  9/13 points to pass
Credits, Certificates, & Evaluation
Final Evaluation
9 Questions
9 Questions Please complete the following evaluation form to share your feedback on this activity.
CME Credits
Up to 9.25 medical credits available  |  Certificate available
Up to 9.25 medical credits available  |  Certificate available
Acknowledgement of MOC Submission
Please review and agree to the terms to continue.
Please review and agree to the terms to continue.
MOC Points
Up to 9.25 medical credits available  |  Certificate available
Up to 9.25 medical credits available  |  Certificate available
LIVE Q&A Session Recording
LIVE Q&A Session Recording
Select the "View On-Demand Recording" button to begin.
Select the "View On-Demand Recording" button to begin.

Upon completion of this activity, learners will be able to: 

  • Discuss the diagnosis, natural history, and therapies for liver diseases leading to liver transplantation;
  • Discuss the management of patients awaiting liver transplantation;
  • Discuss the immediate post-operative and long-term management of liver transplant recipients;
  • Discuss current organ allocation policy and its effects on selecting potential liver transplant recipients.


  • Hepatologists
  • Fellows/ Trainees
  • Gastroenterologists
  • Physician Assistants
  • Surgeons

CME 
The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 9.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Claiming CME Credits 

Physicians and other health care professionals seeking AMA PRA Category 1 Credits™ for this enduring continuing medical education activity must complete an evaluation by December 31, 2022. The CME evaluation will be available to you upon completion of the on-demand course.

Maintenance of Certification
American Board of Internal Medicine (ABIM) MOC Statement 
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

American Board of Pediatrics Maintenance of Certification (MOC) Statement
Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 9.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC points.

Claiming MOC Points 
Physicians seeking ABIM and/or ABP MOC Points must complete the electronic CME and MOC evaluation by December 31, 2022. MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

MOC points are available for ABIM board certified physicians only.

DISCLOSURE OF CONFLICTS OF INTEREST

AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

The organizers and faculty have reported the following disclosures:

Faculty

Andrew Aronsohn, MD
Nothing to disclose

Carl Berg, MD, FAASLD      
Scientific Consulting: Mallinckrodt Pharmaceuticals

Peter Chin-Hong, MD          
Grants/Research Support: Karius

Oren Fix MD, MSc, FAASLD           
Other (eg. Expert testimony): US Attorney (District of Oregon)

Jaquelyn Fleckenstein, MD, FACP, FAASLD       
Nothing to disclose

Catherine Frenette, MD       
Scientific Consulting: Bayer; Speakers Bureau: Bayer, Gilead

Stevan Gonzalez, MD          
Speakers Bureau: Abbvie, Salix

Janice Jou, MD, MHS          
Nothing to disclose

Laura Kulik, MD       
Nothing to disclose

Jennifer Lai, MD       
Scientific Consulting: Axcella Health, Inc.
Advisory Committees and/or Review Panels: Biomarin (one-time only on 9/20/2019, not an ongoing relationship), Ambys Medicines, Inc. (terminated on 12/13/2019)

Michael Leise, MD   
Nothing to disclose

David Levi, MD         
Nothing to disclose

Josh Levitsky, MD, MS, FAASLD, FAST   
Grants/Research Support: Novartis
Scientific Consulting: Novartis
Speakers Bureau: Gilead

Henry Lin, MD          
Nothing to disclose

Michael Lucey, MD, FAASLD         
Grants/Research Support: Abbvie, NIAAA, PharmaSolutions, Intercept Pharma, Exact Sciences

Erin Maynard, MD    
Nothing to disclose

K. Gautham Reddy, MD, FAASLD 
Grants/Research Support: CymaBay, Genfit, Target PharmaSolutions, Arrowhead, Gilead
Speakers Bureau: Intercept, Dova
Leadership in Related Society: Member, Training Committee: American College of Gastoneterology

Mark Russo MD, MPH, FAASLD    
Other (eg. Expert testimony): S Marshall
Speakers Bureau: All speakers bureau contracts terminate 12/31/19

Amit Singal, MD, MS, FAASLD      
Scientific Consulting: Bayer Pharmaceuticals, Eisai, Exelixis, Wako Diagnostics

Ryan Taylor, MD      
Speakers Bureau: Abbvie, Inc., Bristol-Myers Squibb, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc.

Lisa VanWagner, MD, MSc 
Grants/Research Support: Gore Medical
Speakers Bureau: Salix Pharmaceuticals, Gore Medical
Scientific Consulting: Gilead

Zobair Younossi, MD, MPH, FAASLD       
Advisory Committees and/or Review Panels: Gilead, BMS, Intercept, Abbvie and GSK
Scientific Consulting: Gilead, Intercept

Maintenance of Certification Committee

Curtis K. Argo, MD, MS, FAASLD
Nothing to disclose

Raymond T. Chung, MD, FAASLD 
Data Safety Monitoring Board for Industry or Commercial Enterprise: DSMB Alnylam
Grant/Research Support: Abbive, Gilead Sciences, Boehringer Ingelheim, Roche, Janssen, Merck, Kaleido, Synlogic

Debra Guss, DNP, RN, ANP-C
Nothing to disclose 

Steven K. Herrine, MD, FAASLD
Grant/Research Support: Gilead, BMS, Galectin, Intercept

Vandana Khungar, MD, MSc
Nothing to disclose 

Ayman A. Koteish, MD, FAASLD
Nothing to disclose

Ryan M. Kwok, MD
Nothing to disclose

Smruti R. Mohanty, MD, MS
Advisory Committees and/or Review Panels: Education Committee Member, the Alliance for Academic Internal Medicine (AAIM) (July 2016-19) Editorial Board, World Journal of Gastroenterology (2007-Present) Editorial Board, Digestive Disease & Science (2009-Present) Editorial Board, World Journal of Hepatology (2009-Present) Reviewer: Hepatology, Clinical Gastroenterology & Hepatology, Digestive Disease & sciences, Post Graduate Medical Journal, World Journal of Gastroenterology World Journal of Hepatology
Speaker's Bureau: Gilead Science, Merck, Abbvie and Intercept

Heather M. Patton, MD, FAASLD
Grant/Research Support: Gilead Sciences

K. Gautham Reddy, MD, FAASLD
Grants/Research Support: Merck, Intercept, Genfit
Scientific Consulting: Intercept
Speaker's Bureau: Intercept Dova
Advisory Committees and/or Review Panels: American College of Gastroenterology 

Mark W. Russo, MD, MPH, FAASLD
Commercial Speaker's Bureau: Gilead, Abbvie, Intercept, Salix

Grace L. Su, MD, FAASLD
Stock Shareholder: My husband and son have equity interest in Applied Morphomics and Prenovo

Ryan M. Taylor, MD
Speaker’s Bureau: Merck, Inc., Abbvie, Inc., Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Bristol-Myers Squibb

Helen S. Te, MD, FAASLD
Grants/Research Support: Conatus Pharmaceuticals, Gilead Sciences, Abbvie

Katie Duggan, BA
Staff Liaison
Nothing to disclose

Training and Workforce Committee

Jessica Davis, MD
Nothing to disclose

Aparna Goel, MD 
Nothing to disclose

Nitika Arora Gupta, MD, DCH, DNB, MRCPCH
Nothing to disclose

Janice Jou, MD, MHS 
Nothing to disclose

Brian Kim, MD 
Nothing to disclose

Steven Krawitz, MD 
Nothing to disclose

Sylvia M. Lempit, MSN 
Nothing to disclose

Christina Cress Lindenmeyer, MD
Scientific Consulting: Merck Manuals

Nayan Patel, DO, MPH
Nothing to disclose

K. Gautham Reddy, MD, FAASLD 
Grants/Research Support: Merck, Intercept, Genfit
Scientific Consulting: Intercept
Speaker's Bureau: Intercept Dova
Advisory Committees and/or Review Panels: American College of Gastroenterology 

Mary E. McCarthy Rinella, MD, FAASLD 
Scientific Consulting: NGM, Gilead, Intercept, Novartis
Data Safety Monitoring Board for Industry or Commercial Enterprise: TREAT Consortium

Ian R. Schreibman, MD 
Nothing to disclose

Amy Taylor, MD 
Nothing to disclose

Georgios Tsoulfas, MD 
Nothing to disclose 

Katie Duggan, BA
Staff Liaison
Nothing to disclose

AASLD Staff 

Heather Carnahan
Nothing to disclose

Dominique Clayton
Nothing to disclose

Julie Deal
Nothing to disclose 

Katie Duggan
Nothing to disclose

Matthew D’Uva
Nothing to disclose

Denise Seise
Nothing to disclose

Suzanne Thibeault
Nothing to disclose

Anne Wrobel
Nothing to disclose